Day: February 8, 2024

Biotalys Enters into Academic Collaborations with Key Scientific Leaders in Europe and U.S.

Written by Customer Service on February 8, 2024. Posted in Public Companies.

Cooperations will support Biotalys’ targeted approach to biocontrol development and help to advance earlier-stage programs Ghent, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) — Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for crop protection, today announced that the company has entered into several academic collaborations with leading researchers in plant pathology in both Europe and the U.S. Biotalys is developing a series of biocontrols to support growers in protecting their crops from pests and diseases. The company’s R&D program BioFun-4 was initiated last year to develop a biofungicide against Phytophthora infestans, an oomycete (water mould) that causes late blight/potato blight, a serious disease that particularly affects fruit and vegetable crops...

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Written by Customer Service on February 8, 2024. Posted in Earnings Releases And Operating Results.

Total-sales growth in FY 2023 of 6.7% at CER1 (3.4% as reported) included strong sales from the growth platforms2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS operating margin of 26.1%), based on further enrichment of the pipeline and accelerated R&D investment, mainly from recent acquisitionsFinancial guidance for 20243 comprises total-sales growth4 greater than 6.0% at CER1 and a core operating margin5 around 30% of total sales, including the impact of four potential launches and an advancing pipelineA new phase of growth and mid-term financial outlook were outlined at the December 2023 capital-markets dayPARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and...

Societe Generale: Fourth quarter & 2023 full year results

Written by Customer Service on February 8, 2024. Posted in Earnings Releases And Operating Results.

RESULTS AT 31 DECEMBER 2023 Press release Paris, 8 February 2024 AFTER A YEAR OF TRANSITION AND TRANSFORMATION IN 2023, A YEAR FOCUSED ON THE EXECUTION OF OUR NEW STRATEGIC ROADMAP IN 2024 FULL-YEAR RESULTS Revenues of EUR 25.1 billion, down by -7.6% vs. 2022Reported cost-to-income ratio at 73.8%, stable operating expenses (+0.3% vs. 2022) at constant perimeter1, transformation charges of around EUR 730 million in 2023Low cost of risk at 17 basis points, high S1/S2 inventory at ~EUR 3.6 billion at end 2023 Group net income of EUR 2.5 billion, up +37% vs. 2022 Reported ROTE at 4.2% CET 1 ratio of 13.1%2 at end-2023, around 340 basis points above regulatory requirement Liquidity Coverage Ratio at 160% at end-2023 Deposit base up by around +4% vs. 2022 QUARTERLY RESULTS Quarterly revenues...

WTW appoints Roy Nakazawa as Head of Japan and Head of Corporate Risk & Broking Japan

Written by Customer Service on February 8, 2024. Posted in Public Companies.

SINGAPORE, Feb. 08, 2024 (GLOBE NEWSWIRE) — WTW, (NASDAQ: WTW), a leading global advisory and broking solutions company, today announced the appointment of Ryohei (Roy) Nakazawa as its new Head of Japan and Head of Corporate Risk and Broking (CRB) Japan effective 1 April 2024. Based in Tokyo, Roy will oversee the growth strategies and operations of WTW across its business in Japan and lead its CRB business in the country. He will report to Luke Ware, Head of CRB Asia, as well as Simon Weaver, Head of Asia Pacific and Head of CRB Asia Pacific. Roy has a distinguished career spanning over 35 years in the broking, insurance and reinsurance industry in Japan and the US. He will join WTW from STARR Insurance Japan where he is currently the CEO and legal representative. Commenting on this appointment, Luke Ware says, “Roy’s global insurance...

WEMIX3.0 welcomes Sygnum as Node Council Partner “WONDER 18”

Written by Customer Service on February 8, 2024. Posted in Public Companies.

Wemade is proud to announce that Sygnum, a global digital asset banking group, is joining the WEMIX3.0 Mainnet’s Node Council Partners as “WONDER 18”. Singapore , Feb. 07, 2024 (GLOBE NEWSWIRE) —Sygnum will contribute its digital asset expertise and operational experience as a regulated bank to further enhance the reliability of the WEMIX3.0 Mainnet The banking group will also participate in its protocol governance and contribute to the expansion of the WEMIX ecosystem Leading global web3 developer Wemade is proud to announce that Sygnum, a global digital asset banking group, is joining the WEMIX3.0 Mainnet’s Node Council Partners as “WONDER 18”. The NCPs, known as 40 WONDERS (WEMIX On-chain Network of Decentralized Ecosystem Regulators), validate transactions and blocks on the blockchain, while maintaining connections...

Rogers Communications Inc. Announces Pricing of US$2.5 billion Offering of US Dollar Senior Notes

Written by Customer Service on February 8, 2024. Posted in Public Companies.

TORONTO, Feb. 07, 2024 (GLOBE NEWSWIRE) — Rogers Communications Inc. (TSX: RCI.A and RCI.B) (NYSE: RCI) (“RCI”) announced today that it has priced a public offering of two series of US dollar senior notes with an aggregate principal amount of US$2.5 billion, consisting of US$1.25 billion of 5.00% senior notes due 2029 and US$1.25 billion of 5.30% senior notes due 2034 (collectively, the “Notes”). The net proceeds from the issuance will be approximately US$2.46 billion. RCI expects to use the net proceeds from the issuance to repay certain of its outstanding indebtedness, including a portion of the borrowings under its term loan facility used to partially fund its acquisition of Shaw Communications Inc. The sale of the Notes is expected to close on February 9, 2024. The Notes will be issued pursuant to a prospectus supplement and...

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Written by Customer Service on February 8, 2024. Posted in Public Companies.

Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research centers with large PH-HFpEF populations Tenax forecasts topline LEVEL data will be available second half of 2025 CHAPEL HILL, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the first patient has enrolled in the Company’s Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250). “We are pleased to announce the enrollment of our first patient in the Phase 3 LEVEL...

Day: February 8, 2024

Biotalys Enters into Academic Collaborations with Key Scientific Leaders in Europe and U.S.

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Societe Generale: Fourth quarter & 2023 full year results

WTW appoints Roy Nakazawa as Head of Japan and Head of Corporate Risk & Broking Japan

WEMIX3.0 welcomes Sygnum as Node Council Partner “WONDER 18”

Rogers Communications Inc. Announces Pricing of US$2.5 billion Offering of US Dollar Senior Notes

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals